Home
    Disclaimer
    ← Back to MDEA
    MDEA molecular structure

    MDEA Stats & Data

    Psychedelic Stimulant Empathogen Research-chemical
    Mde Eve
    PubChem CID 105039
    PubChem
    MW207.27
    FormulaC12H17NO2
    LogP2.5
    IUPAC1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine
    SMILESCCNC(C)CC1=CC2=C(C=C1)OCO2
    InChIKeyPVXVWWANJIWJOO-UHFFFAOYSA-N
    Chemical Class Amphetamine
    Psychoactive Class Psychedelic / Stimulant

    Receptor Profile

    Receptor Actions

    Inhibitors
    Serotonin-dopamine-norepinephrine reuptake inhibitor (SNDRI)
    Other
    Serotonin-dopamine-norepinephrine releasing agent (SNDRA)

    Toxicity

    PsychonautWiki

    Short-term physical health risks of MDEA consumption include dehydration, insomnia, hyperthermia, and hyponatremia. Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive perspiration puts the body at further risk as the stimulatory and euphoric qualities of the drug may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further. The exact toxic dosage is unknown, but considered to be far greater than its active dose.

    Organ-specific toxicity

    As with MDMA, the neurotoxicity of MDEA use has long been the subject of debate. Scientific study has resulted in the general agreement that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of MDEA is likely to be neurotoxic and cardiotoxic in some form. Like other powerful serotonin releasing agents, MDEA is thought to cause down-regulation of serotonin reuptake transporters in the brain.

    Effect Profile

    Curated + 9 Reports
    Psychedelic 1.0

    Mild body load with low headspace

    Visual Intensity×3
    0
    Headspace Depth×3
    1
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    5
    Empathogen 4.4

    Moderate euphoria with mild stimulation and sensory enhancement, low empathy

    Empathy / Social Openness×3
    3
    Euphoria / Mood Elevation×2
    6
    Stimulation×1
    5
    Sensory Enhancement×1
    5
    Stimulant 4.2

    Strong anxiety/jitters with moderate euphoria, mild stimulation, low focus

    Stimulation / Energy×3
    4
    Euphoria / Mood Lift×2
    7
    Focus / Productivity×2
    3
    Anxiety / Jitters×1
    8
    Based on reports from:
    PiHKAL PiHKAL #106: MDE Erowid Experience Reports PsychonautWiki MDEA

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 36d Baseline ~90d

    Experience Report Analysis

    Erowid
    9 Reports
    2000–2012 Date Range
    2 With Age Data
    19 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 9 experience reports (9 Erowid)

    9 Reports
    19 Effects Detected
    8 Positive
    8 Adverse
    3 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 8

    Focus Enhancement 66.7% 70%
    Stimulation 66.7% 70%
    Color Enhancement 55.6% 70%
    Empathy 55.6% 70%
    Euphoria 55.6% 70%
    Tactile Enhancement 55.6% 70%
    Body High 33.3% 70%
    Introspection 33.3% 70%

    Adverse Effects 8

    Confusion 55.6% 70%
    Jaw Clenching 55.6% 70%
    Increased Heart Rate 44.4% 70%
    Anxiety 44.4% 70%
    Sweating 44.4% 70%
    Nausea 44.4% 70%
    Headache 33.3% 70%
    Muscle Tension 33.3% 70%

    Real-World Dose Distribution

    62K Doses

    From 12 individual dose entries

    Oral (n=7)

    Median: 100.0mg 25th: 100.0mg 75th: 137.5mg 90th: 150.0mg
    mg/kg median: 1.378 mg/kg 75th: 1.488

    Form / Preparation

    Most common forms and preparations reported

    Read full reports on Erowid →

    Legal Status

    Controlled internationally under the UN Convention on Psychotropic Substances 1971.
    Country Status Notes
    Austria MDEA is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
    Brazil MDEA is illegal to possess, produce or sell as it is listed on Portaria SVS/MS nº 344 as "MDE".
    Canada MDEA is listed on the CSDA in Schedule I.
    France MDEA is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.
    Germany MDEA is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of April 15, 1991. It is illegal to manufacture, possess, import, export, buy, sell, procure or to dispense it without a license. ( MDE )
    Switzerland MDEA is a controlled substance specifically named under Verzeichnis D.
    United Kingdom MDEA is a Class A drug.
    United States In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA. MDEA was made a Schedule 1 substance in the United States on October 15, 1987.

    References

    Data Sources

    Cited References

    ← Back to MDEA